Skip to content

Development of a Methamphetamine Early Intervention

Development of a Methamphetamine Early Intervention

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01174654
Enrollment
127
Registered
2010-08-03
Start date
2006-12-31
Completion date
2009-04-30
Last updated
2012-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behavioral Research, HIV, Methamphetamine, Sexual Behavior

Brief summary

Methamphetamine abuse has a strong and consistent epidemiologic association with high-risk sexual behavior and both prevalent and incident HIV in men who have sex with men (MSM), and some authorities have advocated methamphetamine treatment as an HIV prevention strategy. However, methamphetamine interventions have not been evaluated in controlled trials, nor have they been implemented and assessed outside of substance abuse treatment programs. This application proposes preliminary investigations to adapt a methamphetamine treatment intervention previously associated with decreased sexual-risk taking among MSM for use as an early intervention among MSM in Seattle, Washington. Sixty methamphetamine-using MSM will be enrolled in a randomized controlled trial of contingency management (CM) versus no intervention. CM participants will have their urine tested for methamphetamine 3 times weekly for 12 weeks, and will receive vouchers of escalating value when their urines test negative; vouchers will be withheld when participants' urines test positive for methamphetamine or participants miss urine testing visits. All participants will undergo urine methamphetamine testing and audio-computer assisted self-interviews on sexual behavior and substance use at baseline and at 6 week intervals for 6 months. Participants will be tested for HIV, syphilis, rectal gonorrhea and chlamydial infection, and pharyngeal gonorrhea at baseline and at 3 and 6 month follow-up. The study will determine how often MSM will initiate and complete the early intervention, and will longitudinally measure unsafe sexual behaviors among intervention and control participants. Study results will determine the feasibility of instituting and studying CM as an early intervention; define whether the intervention is sufficiently promising to justify a larger, definitive randomized controlled trial; and will provide estimates for defining the number of participants such a trial would require.

Interventions

BEHAVIORALContingency management

A 12-week contingency management intervention

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
University of Washington
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Anal sex with another man in the month prior to enrollment * Use of methamphetamine on at least 2 days in the month prior to enrollment

Exclusion criteria

* Plans to move from the study catchment area within 6 months of enrollment * A mutually monogamous relationships with a man of the same HIV status lasting 2 or more years

Design outcomes

Primary

MeasureTime frame
Non-concordant unprotected anal intercourseBaseline, 6, 12, 18, 24 weeks

Secondary

MeasureTime frame
Number of non-concordant unprotected anal intercourse partnersBaseline, 6, 12, 18, 24 weeks
Stimulant (methamphetamine and crack/cocaine) urinalysesBaseline, 6, 12, 18, 24 weeks
Self-reported methamphetamine useBaseline, 6, 12, 18, 24 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026